Oncology
Takeda announces launch of Framework to help support patient access to life-extending combination treatments
February 25, 2025Business Services Cancer, HIV/AIDS, Immunology, NHS, NICE, Oncology, Takeda, VPAG, patient access
The Conceptual Implementation Framework outlines critical points within the UK healthcare access ecosystem to help improve the introduction of combination …
MHRA approve new treatment combo for transplant-ineligible multiple myeloma patients
January 30, 2025Research and Development MHRA, Oncology, approvals, multiple myeloma, rare diseases
The Medicine and Healthcare products Regulatory Agency (MHRA) has approved quadruplet therapy, SARCLISA (isatuximab) in combination to treat multiple myeloma …
Research collaboration announced between Oxford University and GSK
January 27, 2025Research and Development Cancer, Oncology, Oxford University, neoantigens, partnership, research and development
The GSK-Oxford Cancer Immuno-Prevention Programme was announced at the end of January and will focus on researching the prevention of …
Combination first-in-line treatment approved for patients with non-small cell lung cancer
January 23, 2025Research and Development J&J Innovative Medicine, Oncology, approval, non-small cell lung cancer
Johnson & Johnson Innovative Medicine have announced that the European Commission (EC) has approved a marketing authorisation for the combination …
University of Sheffield trial highlights immunotherapy-related improved survival rates for bladder cancer patients
January 14, 2025Research and Development Endocrinology, Oncology, Sheffield, astranzeneca, bladder cancer, immunotherapy, patients
The University of Sheffield, UK, have announced study results for its trial into the survival rates of patients with operable …
NDA in China receives priority review status for lung cancer treatment
January 3, 2025Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …
Johnson & Johnson receive MHRA approval for BALVERSA
November 8, 2024Research and Development J&J Innovative Medicine, Oncology, Urology, bladder cancer
BALVERSA (erdafitinib) has been granted marketing approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment …
Valneva Scotland supports local cancer charity Team Jak Foundation
October 31, 2024Support Services Oncology, Scotland, Valneva Scotland, cancer charity, paediarics, vaccines
Valneva Scotland, the country’s largest vaccine producer, has partnered with local West Lothian-headquartered charity, Team Jak, helping towards the organisation’s …
Third application for Orion’s prostate cancer drug submitted by partner Bayer
September 23, 2024Bayer, Cancer, Oncology, orion, prostate cancer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
August 27, 2024Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …
New gastric & gastro-oesophageal junction cancer treatment VYLOY™ ▼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain
August 16, 2024GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer
Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …
First oral treatment for hormone-sensitive prostate cancer recommended by NICE
August 15, 2024Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer
Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …
China CDE clears Phase 3 Study of Lisafltoclax in Newlly Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome
August 13, 2024Clinical Research, Research and Development Ascentage Pharma, Oncology
The China Centre for Drug Evaluation (CDE) has cleared the registrational phase 3 study of lisaftoclax in combination with azacitadine …
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
August 12, 2024Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells
Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
August 7, 2024Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …
Latest content
FibroFind appoints Lee Borthwick as CEO
